GUIDELINES ON RENAL CELL CANCER

Introduction

Renal Cell Cancer is characterised by a constant rise in incidence over the last 50 years, with a predominance of men over women and an incidence peak in the 6th and 7th decade. There are no generally accepted risk factors for RCC although there are some epidemiologic data indicating that a smoking habit, obesity or exposure to certain heavy metals such as cadmium may favour the development of RCCs.

Diagnosis

Clinical signs and symptoms of RCC:

- haematuria
- persistent lower back pain
- a mass in the abdomen
- fatigue
- weight loss
- fever not obviously associated with infection
- and swelling of the legs

Generally the diagnosis is made through an abdominal ultrasound performed for various reasons.
Standard radiological procedure:
• abdominal CT-scan with and without contrast medium (It serves to document the diagnosis of RCC and provides information on the function and morphology of the contralateral kidney)

Additional diagnostic procedures:
• magnetic resonance imaging (MRI)
• angiography or fine needle biopsy, have a very limited role, but may be considered in selected cases.

In case of haematuria, additional tumours of the genitourinary tract should be excluded. The most commonly assessed laboratory parameters are:
• Haemoglobin and erythrocyte sedimentation rate: prognosis
• Creatinine: overall kidney function
• Alkaline phosphatase: liver metastasis, bone metastasis. Serum calcium is frequently included in the preoperative assessment because of its association with paraneoplastic manifestation, which may have clinical implications.

Classification
The TNM (UICC, 2002) classification is recommended

<table>
<thead>
<tr>
<th>T</th>
<th>Primary tumour</th>
</tr>
</thead>
<tbody>
<tr>
<td>TX</td>
<td>Primary tumour cannot be assessed</td>
</tr>
<tr>
<td>T0</td>
<td>No evidence of primary tumour</td>
</tr>
<tr>
<td>T1</td>
<td>Tumour 7 cm or less in greatest dimension, limited to the kidney</td>
</tr>
<tr>
<td>T1a</td>
<td>Tumour 4 cm or less</td>
</tr>
<tr>
<td>T1b</td>
<td>Tumour more than 4 cm but not more than 7 cm</td>
</tr>
</tbody>
</table>

Renal Cell Cancer
T2 Tumour more than 7 cm in greatest dimension, limited to the kidney
T3 Tumour extends into major veins or directly invades adrenal gland or perinephric tissues but not beyond Gerota fascia
  T3a Tumour directly invades adrenal gland or perinephric tissues¹ but not beyond Gerota fascia
  T3b Tumour grossly extends into renal vein(s)² or vena cava or its wall below diaphragm
  T3c Tumour grossly extends into vena cava or its wall above diaphragm
T4 Tumour directly invades beyond Gerota fascia

N Regional lymph nodes
NX Regional lymph nodes cannot be assessed
N0 No regional lymph node metastasis
N1 Metastasis in a single regional lymph node
N2 Metastasis in more than one regional lymph node

M Distant metastasis
MX Distant metastasis cannot be assessed
M0 No distant metastasis
M1 Distant metastasis

¹ Includes renal sinus (peripelvic) fat
² Includes segmental (muscle-containing) branches

Robson’s classification (1969) is commonly used and the relationship with TNM 2002 is as follows:
• Robson’s Stage I = T1-2
• Robson’s Stage II = T3a
• Robson’s Stage IIIa = T3b-c
• Robson’s Stage IVa = T4
• Robson’s Stage IIIb = N1-2
• Robson’s stage IVb = M1

Traditionally RCC have been classified according to the nuclear or cellular morphology. New morphologic, cytogenetic and molecular studies make it possible to distinguish five types of carcinomas:
• Clear - cell: 60 - 85%
• Chromophilic: 7 - 14%
• Chromophobic: 4 - 10%
• Oncocytic: 2 - 5%
• Collecting duct: 1 - 2% (10).

Treatment
Surgery is the main treatment for renal cell carcinoma, offering a reasonable chance of curing the disease. The chances of cure by surgery most strongly depend on stage (primarily) and grade (secondarily). Standard operative procedure is a radical nephrectomy including Gerota’s fascia. There is no evidence to favour a specific surgical approach. In selected cases of small (<4 cm) peripheral lesions, an organ sparing approach may be considered.
• Chemotherapy, apart for Wilm’s tumor in children, RCC seems to be very resistant to chemotherapy
• Radiation therapy (in case of bone-metastases or spreading to the brain)
• Immunotherapy – still under investigation but results are promising
• Experimental therapies
Follow up

Follow up of patients with RCC after surgical treatment is recommended to detect local recurrence and distant metastases as early as possible to permit additional treatment when indicated and if possible.

Table 1: Recommended follow-up scheme for renal cell carcinoma

<table>
<thead>
<tr>
<th>Stage</th>
<th>Visit</th>
<th>Examination</th>
</tr>
</thead>
<tbody>
<tr>
<td>All T</td>
<td>4-6 weeks after surgery</td>
<td>Physical ex.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Creatinine</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hb</td>
</tr>
<tr>
<td>T1, T2</td>
<td>Every 6 months for 3 years</td>
<td>Physical exam</td>
</tr>
<tr>
<td></td>
<td>Every year from 3 to 5 years</td>
<td>Chest X-ray</td>
</tr>
<tr>
<td>T3, T4</td>
<td>Every 6 months for 3 years</td>
<td>Physical exam</td>
</tr>
<tr>
<td></td>
<td>Every year from 3 to 10 years</td>
<td>Chest X-ray</td>
</tr>
<tr>
<td></td>
<td>c</td>
<td>Retroperitoneal imaging</td>
</tr>
</tbody>
</table>

AP = alkaline phosphatase; LR = local recurrence; LN = lymph node

a If elevated preoperatively (recurrent or persisting elevation suggests distant metastases or residual tumour) when bone pain is present, suspicion of bone or liver metastasis.

b If the postoperative level is abnormal, it should be repeated at the regular visits.

c There is a small, but continuous, risk of recurrence or metastasis from 5 - 15 yrs.
This short booklet text is based on the more comprehensive EAU guidelines (ISBN 90-806179-8-9), available to all members of the European Association of Urology at their website - http://www.uroweb.org.

<table>
<thead>
<tr>
<th>Optional</th>
<th>Purpose</th>
</tr>
</thead>
<tbody>
<tr>
<td>AP²</td>
<td>Exclude complications of surgery and LR and LN metastases. Exclude pulmonary metastases and LR after partial nephrectomy. To detect LR, contralateral metastases or neo-occurrence.</td>
</tr>
<tr>
<td>Kidney imaging</td>
<td>Establish remaining kidney function. To check recovery of perioperative blood loss.</td>
</tr>
</tbody>
</table>

Renal Cell Cancer